A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies | C4C

The Eisai – Delphia study is investigating a new therapy for people with a diagnosis of probable Dementia with Lewy bodies. The study design means that participants will be allocated to either the active treatment group or the placebo (dummy drug) group, so there is a 50-50 chance that a participant may be receiving the active treatment. To prevent biasness, the study will be double-blinded, which means neither the participant nor the research team will know whether the participant has been allocated to the treatment or the placebo group. We would like to perform a CRIS search to identify MHOA (Mental Health of Older Adults & Dementia) patients who may be eligible for this study. This is a multi centre study, where King’s College London is one of the participating site’s, collaborating with three participating diagnostic specialist memory clinics, Community Mental Health Teams and Parkinson’s Clinic in South London & Maudsley NHS foundation Trust and we (MHOA (Mental Health of Older Adults & Dementia) research assistants) will be contacting potentially eligible patients ourselves.